A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Intravenous Study in Healthy Subjects and a Multiple-Dose Intravenous Study in Asthmatic Subjects to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of CNTO 3157.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2012
At a glance
- Drugs CNTO 3157 (Primary)
- Indications Asthma
- Focus Adverse reactions
- 16 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Sep 2011 Planned end date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 06 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.